n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance And Outlines Company Progress

ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance And Outlines Company Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2015 and issued 2016 product revenue guidance.

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City.

Insider Trading Alert - AEP, JBSS And ARIA Traded By Insiders

Insider Trading Alert - AEP, JBSS And ARIA Traded By Insiders

Stocks with insider trader activity include AEP, JBSS and ARIA

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2015 Financial Results

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2015 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 23, 2016, before the market opens.

AP32788 (gray) Shown Binding To EGFR (Photo: Business Wire)

AP32788 (gray) Shown Binding To EGFR (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the U.

ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays

ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays

Barclays began coverage of ARIAD Pharmaceuticals (ARIA) stock with an ‘underweight’ rating on Tuesday morning.

ARIAD Reports Inducement Grant To New Chief Executive Officer

ARIAD Reports Inducement Grant To New Chief Executive Officer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Executive Officer, Paris Panayiotopoulos.

Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)

Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD Announces Termination Of Shareholder Rights Plan

ARIAD Announces Termination Of Shareholder Rights Plan

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its Board of Directors has unanimously approved the termination of the Company's Section 382 Rights Agreement, or the Rights Plan, originally adopted on...

Alexander J. Denner, Ph.D (Photo: Business Wire)

Alexander J. Denner, Ph.D (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the election of Alexander J.

ARIAD And Otsuka Submit New Drug Application In Japan For Ponatinib

ARIAD And Otsuka Submit New Drug Application In Japan For Ponatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co.

Relative Strength Alert For ARIAD Pharmaceuticals

Relative Strength Alert For ARIAD Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Paris Panayiotopoulos, President And Chief Executive Officer Of ARIAD Pharmaceuticals, Inc., Effective January 1, 2016. (Photo: Business Wire).

Paris Panayiotopoulos, President And Chief Executive Officer Of ARIAD Pharmaceuticals, Inc., Effective January 1, 2016. (Photo: Business Wire).

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), effective January 1, 2016.

ARIAD Announces Pricing And Reimbursement Negotiations For Iclusig In France To Continue Into 2016

ARIAD Announces Pricing And Reimbursement Negotiations For Iclusig In France To Continue Into 2016

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will continue negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig ®...

ARIAD Announces Initiation Of OPTIC-2L Randomized Phase 3 Trial Of Ponatinib Vs. Nilotinib In Second-Line Patients With Chronic-Phase Chronic Myeloid Leukemia

ARIAD Announces Initiation Of OPTIC-2L Randomized Phase 3 Trial Of Ponatinib Vs. Nilotinib In Second-Line Patients With Chronic-Phase Chronic Myeloid Leukemia

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a randomized Phase 3 trial of Iclusig ® (ponatinib) in second-line patients with chronic myeloid leukemia (CML) in the chronic phase...

Interesting ARIA Put Options For January 2016

Interesting ARIA Put Options For January 2016

Investors in ARIAD Pharmaceuticals, Inc. saw new options become available today, for the January 2016 expiration.

ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting

ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the schedule of several data presentations on Iclusig ® (ponatinib) that will take place at the 57 th Annual Meeting of the American Society of...

ARIAD Reports Third Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Reports Third Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2015, including revenue from sales of Iclusig ® (ponatinib).

ARIAD To Webcast Conference Call On Third Quarter 2015 Financial Results

ARIAD To Webcast Conference Call On Third Quarter 2015 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2015 financial results on Tuesday, November 3, 2015, before the market opens.

First Week of December 18th Options Trading For ARIAD Pharmaceuticals (ARIA)

First Week of December 18th Options Trading For ARIAD Pharmaceuticals (ARIA)

Investors in ARIAD Pharmaceuticals, Inc. saw new options begin trading this week, for the December 18th expiration.

ARIA January 2018 Options Begin Trading

ARIA January 2018 Options Begin Trading

Investors in ARIAD Pharmaceuticals, Inc. saw new options begin trading today, for the January 2018 expiration.

ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

First Week of ARIA May 2016 Options Trading

First Week of ARIA May 2016 Options Trading

Investors in ARIAD Pharmaceuticals, Inc. saw new options become available this week, for the May 2016 expiration.

ARIAD Announces Full Enrollment In Phase 2 ALTA Trial Of Brigatinib

ARIAD Announces Full Enrollment In Phase 2 ALTA Trial Of Brigatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has achieved full enrollment in the pivotal Phase 2 ALTA trial of its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib.

Tetraphase Executive Profits Hours Before Stock Plummets

Tetraphase Executive Profits Hours Before Stock Plummets

A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.

Insider Trading Alert - SABR, DLTR And ARIA Traded By Insiders

Insider Trading Alert - SABR, DLTR And ARIA Traded By Insiders

Stocks with insider trader activity include SABR, DLTR and ARIA

Interesting ARIA Put And Call Options For October 23rd

Interesting ARIA Put And Call Options For October 23rd

Investors in ARIAD Pharmaceuticals, Inc. saw new options begin trading today, for the October 23rd expiration.

Today's Dead Cat Bounce Stock Is ARIAD Pharmaceuticals (ARIA)

Today's Dead Cat Bounce Stock Is ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Market News: Biogen, Vera Bradley, Ariad Pharmaceuticals

Market News: Biogen, Vera Bradley, Ariad Pharmaceuticals

The stock markets in the United States rebounded today after experiencing sell-off over the past two days. September is historically the worst month for the S&P 500, which declined 3.8% during the...